VENUS

MEDTECH

profession / safety highly efficiency

Venus Medtech is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018.

About us

Venus Medtech (Hangzhou) Inc. is a leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018.

The Company’s self-developed product, VenusA-Valve, is the first transcather aortic heart valve replacement (“TAVR”) product approved by the National Medical Products Administration ("NMPA") and commercialized in China.

Products

Financial Report

News Center

25 Oct, 2018

主动脉瓣狭窄低危患者TAVR安全

More Details

31 Oct, 2019

启明医疗携手2019 PCR-CIT China Chengdu Valves引领创心时代

More Details

02 May, 2020

Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market

More Details

25 Oct, 2018

主动脉瓣狭窄低危患者TAVR安全

More Details

31 Oct, 2019

启明医疗携手2019 PCR-CIT China Chengdu Valves引领创心时代

More Details

02 May, 2020

Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market

More Details

Contact Us

Enquiries

Address: Room 311, 3/F, Block 2, No. 88, Jiangling Road ,
Binjiang District, Hangzhou, PRC

Tel: +86 0571 8675 9022

Fax: +86 0571 8777 2179

Email: inquiry@venusmedtech.com